Valneva SE
ISIN: FR0004056851 | Ticker: VLA | LEI: 969500DIVIP5VKNW4948
Country: France
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.
Year founded2013
Served areaWorldwide
Headcount762
Headquarters6 Rue Alain Bombard, 44800 Saint-Herblain – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 449,164,000.00 | 817,352,000.00 | 621,344,000.00 |
| Noncurrent Assets | N/A | 140,737,000.00 | 231,520,000.00 | 196,685,000.00 |
| Property Plant And Equipment | N/A | 34,779,000.00 | 125,545,000.00 | 112,435,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 35,409,000.00 | 32,700,000.00 | 28,711,000.00 |
| Investment Accounted For Using Equity Method | N/A | 2,130,000.00 | 2,124,000.00 | 0.00 |
| Deferred Tax Assets | N/A | 5,570,000.00 | 3,582,000.00 | 5,637,000.00 |
| Other Noncurrent Assets | N/A | 19,476,000.00 | 19,282,000.00 | 8,299,000.00 |
| Current Assets | N/A | 308,427,000.00 | 585,832,000.00 | 424,660,000.00 |
| Inventories | N/A | 26,933,000.00 | 124,098,000.00 | 35,104,000.00 |
| Current Trade Receivables | N/A | 19,232,000.00 | 44,013,000.00 | 23,912,000.00 |
| Cash and cash equivalents | 64,439,000.00 | 204,394,000.00 | 346,642,000.00 | N/A |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | N/A | 0.00 | 2,134,000.00 |
| Current Restricted Cash And Cash Equivalents | 0.00 | 41,000.00 | 44,000.00 | 2,898,000.00 |
| Other Current Assets | N/A | 57,828,000.00 | 71,036,000.00 | 74,079,000.00 |
| Equity And Liabilities | N/A | 449,164,000.00 | 817,352,000.00 | 621,344,000.00 |
| Equity | 135,153,000.00 | 77,422,000.00 | 170,581,000.00 | 219,797,000.00 |
| Issued Capital | N/A | 13,646,000.00 | 15,786,000.00 | 20,755,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | -73,425,000.00 | -143,279,000.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | -233,549,000.00 | -306,974,000.00 |
| Share Premium | N/A | 244,984,000.00 | 409,258,000.00 | 594,043,000.00 |
| Other Reserves | N/A | 52,342,000.00 | 52,512,000.00 | 55,252,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 77,422,000.00 | 170,581,000.00 | 219,797,000.00 |
| Liabilities | N/A | 371,742,000.00 | 646,771,000.00 | 401,547,000.00 |
| Noncurrent Liabilities | N/A | 195,872,000.00 | 277,791,000.00 | 124,156,000.00 |
| Noncurrent Provisions | N/A | 2,358,000.00 | 8,308,000.00 | 1,320,000.00 |
| Noncurrent Contract Liabilities | N/A | 58,000.00 | 4,741,000.00 | 0.00 |
| Deferred Tax Liabilities | N/A | 412,000.00 | 1,290,000.00 | 694,000.00 |
| Other Noncurrent Liabilities | N/A | 72,000.00 | 69,000.00 | 116,000.00 |
| Longterm Borrowings | N/A | 46,375,000.00 | 50,726,000.00 | 87,227,000.00 |
| Current Liabilities | N/A | 175,870,000.00 | 368,979,000.00 | 277,392,000.00 |
| Current Provisions | N/A | 10,169,000.00 | 48,708,000.00 | 31,257,000.00 |
| Current Contract Liabilities | N/A | 89,578,000.00 | 124,017,000.00 | 9,411,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 83,000.00 | 532,000.00 |
| Other Current Liabilities | N/A | 2,841,000.00 | 4,950,000.00 | 5,523,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 126,196,000.00 | 110,321,000.00 | 348,086,000.00 | 361,303,000.00 |
| Revenue From Sale Of Goods | 129,511,000.00 | 65,938,000.00 | 62,984,000.00 | 114,797,000.00 |
| Other Revenue | -3,315,000.00 | 44,383,000.00 | 285,101,000.00 | 246,506,000.00 |
| Profit Loss From Operating Activities | -811,000.00 | -55,120,000.00 | -61,390,000.00 | -113,443,000.00 |
| Finance Income | 1,449,000.00 | 516,000.00 | 249,000.00 | 260,000.00 |
| Finance Costs | 3,082,000.00 | 10,738,000.00 | 16,964,000.00 | 19,054,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | 1,574,000.00 | -133,000.00 | -5,000.00 | 9,000.00 |
| Profit Loss Before Tax | -870,000.00 | -65,302,000.00 | -69,979,000.00 | -144,815,000.00 |
| Income Tax Expense Continuing Operations | 874,000.00 | -909,000.00 | 3,446,000.00 | -1,536,000.00 |
| Profit (loss) | -1,744,000.00 | -64,393,000.00 | -73,425,000.00 | -143,279,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | -1,744,000.00 | -64,393,000.00 | -73,425,000.00 | -143,279,000.00 |
| Other Adjustments For Noncash Items | 12,704,000.00 | 37,941,000.00 | 56,476,000.00 | 44,070,000.00 |
| Cash Flows From Used In Operations | 7,875,000.00 | 139,759,000.00 | 78,532,000.00 | -245,189,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 2,346,000.00 | 2,021,000.00 | 1,631,000.00 | 154,000.00 |
| Cash Flows From Used In Operating Activities | 5,529,000.00 | 137,738,000.00 | 76,901,000.00 | -245,343,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 0.00 | 8,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 10,502,000.00 | 18,936,000.00 | 92,229,000.00 | 29,246,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | 0.00 | 24,000.00 | 0.00 | 0.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 382,000.00 | 535,000.00 | 942,000.00 | 76,000.00 |
| Interest Received Classified As Investing Activities | 199,000.00 | 107,000.00 | 54,000.00 | 260,000.00 |
| Cash Flows From Used In Investing Activities | -10,685,000.00 | -19,340,000.00 | -93,116,000.00 | -29,054,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | 11,781,000.00 | 50,266,000.00 | 859,000.00 | 39,331,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | 11,684,000.00 | 21,995,000.00 | 1,956,000.00 | 1,793,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 2,709,000.00 | 2,111,000.00 | 2,805,000.00 | 3,048,000.00 |
| Interest Paid Classified As Financing Activities | 2,621,000.00 | 4,711,000.00 | 8,417,000.00 | 9,211,000.00 |
| Cash Flows From Used In Financing Activities | -7,696,000.00 | 21,740,000.00 | 154,504,000.00 | 215,116,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -12,852,000.00 | 140,138,000.00 | 138,288,000.00 | -59,282,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 207,000.00 | -183,000.00 | 3,960,000.00 | -828,000.00 |
| Cash and cash equivalents | 64,439,000.00 | 204,394,000.00 | 346,642,000.00 | N/A |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 20.06.23 | None | Other | Sell | EUR 1,406,228.50 |
| 19.06.23 | None | Other | Sell | EUR 209,629.26 |
| 16.06.23 | None | Other | Sell | EUR 582,493.06 |
| 15.06.23 | None | Other | Sell | EUR 189,503.78 |
| 14.06.23 | None | Other | Sell | EUR 1,519,914.11 |
| 13.06.23 | None | Other | Sell | EUR 187,922.37 |
| 12.06.23 | None | Other | Sell | EUR 733,782.57 |
| 10.05.23 | None | Other | Buy | EUR 0.00 |
FR0004056851
LEI969500DIVIP5VKNW4948
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.